AMENDMENT TO RULES COMMITTEE PRINT 117–13

OFFERED BY MR. CRENSHAW OF TEXAS

Add at the end of subtitle C of title VII the following new section:

SEC. 7. GRANT PROGRAM TO STUDY TREATMENT OF POST-TRAUMATIC STRESS DISORDER USING CERTAIN PSYCHEDELIC SUBSTANCES.

(a) GRANT PROGRAM.—The Secretary of Defense shall carry out a program to award grants to eligible entities to conduct research on the treatment of members of the Armed Forces serving on active duty with post-traumatic stress disorder using covered psychedelic substances.

(b) CRITERION FOR APPROVAL.—The Secretary may award a grant under this section to an eligible entity to conduct research if the Secretary determines that the research involves a therapy that has the potential to demonstrate significant medical evidence of a therapeutic advantage.

(c) ELIGIBLE ENTITIES.—The Secretary may award a grant under this section to any of the following:
(1) A department or agency of the Federal Government or a State government.

(2) An academic institution.

(3) A nonprofit entity.

(d) USE OF GRANT FUNDS.—A recipient of a grant awarded under this section may use the grant to—

(1) conduct one or more phase two clinical trials for the treatment of post-traumatic stress disorder that—

   (A) include members of the Armed Forces serving on active duty as participants in the clinical trial; and

   (B) use individual or group therapy assisted by covered psychedelic substances; or

   (2) train practitioners to provide treatment to members of the Armed Forces serving on active duty for post-traumatic stress disorder using covered psychedelic substances.

(e) PARTICIPATION IN CLINICAL TRIALS.—The Secretary may authorize a member of the Armed Forces to participate in a clinical trial that is conducted using a grant awarded under this section or funds provided under subsection (f) and is authorized pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355), without regard to—
(1) whether the clinical trial involves a substance included in the schedule under section 202 of the Controlled Substances Act (21 U.S.C. 812); or

(2) section 912a of title 10, United States Code (article 112a of the Uniform Code of Military Justice).

(f) ADDITIONAL AUTHORITY.—In addition to awarding grants under this section, the Secretary may provide funds for a clinical research trial using covered psychedelic substances that is authorized pursuant to section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355) and includes members of the Armed Forces as participants in the trial.

(g) DEFINITIONS.—In this section:

(1) The term “covered psychedelic substances” means any of the following:

(A) 3,4-methylenedioxy-methamphetamine (commonly known as “MDMA”).

(B) Psilocybin.

(C) Ibogaine.

(D) 5-Methoxy-N,N-dimethyltryptamine (commonly known as “5-MeO-DMT”).

(2) The term “State” includes any State, district, territory, or possession of the United States.